智通财经APP讯，九芝堂(000989.SZ)公告，公司全资子公司牡丹江友搏药业有限责任公司(简称“友搏药业”)与牵头组长单位复旦大学附属华山医院和参研的四川大学华西医院、中南大学湘雅医院等全国26家临床试验中心组织召开了关于开展“以注射用达托霉素为对照，初步探索静脉输注不同剂量的YB211治疗成人急性细菌性皮肤及皮肤结构感染受试者的有效性和安全性的随机、盲法、阳性药平行对照、多中心的Ⅱ期临床试验”的项目启动会。本次临床试验的启动将进一步推进新药YB211的研发与评价进度。
智通财经APP讯，九芝堂(000989.SZ)公告，公司全资子公司牡丹江友搏药业有限责任公司(简称“友搏药业”)与牵头组长单位复旦大学附属华山医院和参研的四川大学华西医院、中南大学湘雅医院等全国26家临床试验中心组织召开了关于开展“以注射用达托霉素为对照，初步探索静脉输注不同剂量的YB211治疗成人急性细菌性皮肤及皮肤结构感染受试者的有效性和安全性的随机、盲法、阳性药平行对照、多中心的Ⅱ期临床试验”的项目启动会。本次临床试验的启动将进一步推进新药YB211的研发与评价进度。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.